Open Orphan is changing its name as CEO Yamin Khan said the company achieved its ‘key goal’ of double-digit earnings for the first time.
Dublin-based pharma services company Open Orphan announced today (8 September) that it is changing its name to Hvivo next month.
The Open Orphan board believes that the rebranding reflects the company’s core human challenge and early clinical services business.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).